Liver cancer is most often diagnosed through a combination of blood tests and specialized imaging scans, and in many cases, a definitive diagnosis can be made without a biopsy. The process typically begins when a doctor notices something abnormal during routine screening of a high-risk patient or investigates symptoms like unexplained weight loss, abdominal pain, or jaundice. From that first flag to a confirmed diagnosis, the workup can take several weeks.
Physical Exam and Early Signs
The diagnostic process usually starts with a physical examination. Your doctor will feel your abdomen for unusual lumps or changes in the size and shape of the liver, spleen, and surrounding organs. They’ll also check for ascites, an abnormal buildup of fluid in the abdomen that can signal liver disease. Yellowing of the skin and eyes (jaundice) is another physical sign that prompts further testing.
These findings alone can’t confirm cancer, but they tell your doctor whether the liver is functioning normally and whether imaging and blood work are warranted.
Blood Tests That Flag Liver Cancer
The most widely used blood marker for liver cancer is alpha-fetoprotein (AFP), a protein that healthy livers produce in very small amounts. In a healthy person, AFP levels sit below 5 ng/mL. In people with chronic liver disease but no cancer, levels can climb higher, but research has identified 40 ng/mL as a meaningful threshold: above that level, liver cancer can be diagnosed with minimal risk of false positives.
AFP isn’t perfect, though. Its sensitivity ranges from about 40% to 65% depending on the population being tested, and roughly 15% of people with confirmed liver cancer have AFP levels that look completely normal. That means a normal AFP result doesn’t rule cancer out.
A second blood marker, sometimes called PIVKA-II, measures an abnormal form of a clotting protein that liver tumors tend to produce. It outperforms AFP overall, with a sensitivity of 67% and specificity of 91%. Some doctors use both markers together to improve detection accuracy, though availability varies by country. In Japan, PIVKA-II is part of standard clinical practice.
Beyond tumor markers, your doctor will run standard liver function tests. These measure how well your liver processes waste, produces proteins, and clears toxins. The results feed into scoring systems that gauge the severity of any underlying liver disease, which matters because treatment decisions for liver cancer depend not just on the tumor itself but on how much healthy liver function remains.
Imaging Scans: The Centerpiece of Diagnosis
Imaging is where most liver cancer diagnoses are actually confirmed. The two main tools are multiphasic CT scans and MRI, both performed with contrast dye that highlights how blood flows through the liver in distinct phases.
Liver cancer has a characteristic signature on these scans. Tumors tend to light up brightly during the arterial phase, when contrast-rich blood first floods in through the arteries, then fade relative to the surrounding liver tissue during the later venous phase. Radiologists call this pattern “arterial hyperenhancement with venous washout,” and it’s the hallmark of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
This pattern is highly reliable for larger tumors but less so for small ones. Among tumors smaller than 3 centimeters, only about 37% show the classic enhancement-then-washout pattern on CT. Well-differentiated tumors (slower-growing, more closely resembling normal liver cells) are especially tricky: just 13% display the typical pattern, compared to 48% of more aggressive tumors. Very small tumors under 1 centimeter often look identical to normal liver tissue on all phases, making them easy to miss entirely.
The LI-RADS Scoring System
To standardize how radiologists interpret these scans, the medical community developed a scoring system called LI-RADS (Liver Imaging Reporting and Data System). Every suspicious observation in the liver gets assigned a category from LR-1 to LR-5. LR-1 means definitely benign. LR-5 means definite HCC. Categories in between reflect increasing levels of suspicion, with LR-3 and LR-4 observations often requiring follow-up imaging or biopsy to reach a conclusion. This scoring system helps ensure that radiologists across different hospitals interpret scans consistently and that treatment decisions are based on a shared framework.
When a Biopsy Is Needed
One of the things that makes liver cancer unusual compared to many other cancers is that a biopsy is often unnecessary. When imaging shows a classic enhancement pattern in a patient with known risk factors (chronic hepatitis B or C, cirrhosis, heavy alcohol use), doctors can diagnose HCC and begin treatment based on the scan alone.
Biopsy is reserved for cases where imaging findings are atypical, where the scan lands in an intermediate LI-RADS category, or where the type of liver cancer is unclear. A tissue sample can distinguish HCC from other liver tumors, including cancers that spread to the liver from elsewhere in the body. The procedure is guided by ultrasound or CT to ensure the needle reaches the right spot, and it carries a small risk of bleeding or, very rarely, seeding tumor cells along the needle track.
Assessing Liver Function Alongside Cancer
Diagnosing liver cancer is only half the picture. Because most liver cancers develop in livers already damaged by cirrhosis or chronic disease, doctors simultaneously assess how much functional liver remains. This step directly determines which treatments are safe to offer.
The most widely used tool for this is the Child-Pugh score, which combines five clinical measures (including bilirubin levels, albumin, and the presence of ascites) into a grade of A, B, or C. Patients with a Child-Pugh A grade have the best-preserved liver function and qualify for the widest range of treatments, including surgery and newer systemic therapies. Those with a grade C have severe dysfunction, which limits options significantly.
A newer scoring method called ALBI (which stands for albumin-bilirubin) is gaining ground because it relies on just two objective lab values and removes some of the subjectivity baked into Child-Pugh. It’s already standard in Japan and increasingly used elsewhere to predict how patients will respond to treatments ranging from surgery to immunotherapy. For patients being evaluated for liver transplant or surgical removal of part of the liver, additional scoring systems help determine whether the remaining liver can sustain the body after the procedure.
What the Full Workup Looks Like
If you’re going through a liver cancer diagnostic workup, the typical sequence looks something like this. An initial blood draw checks AFP, liver function, and general health markers. If results are concerning, you’ll be scheduled for a multiphasic CT or MRI. If the imaging is conclusive, showing LR-5 characteristics, your team can move straight to staging and treatment planning. If the imaging is ambiguous, a biopsy may follow. Throughout this process, your doctors are also scoring your liver function to map out which treatments your liver can handle.
The NHS notes that it can take several weeks to get all results back. Some of that time is built into scheduling scans and waiting for pathology if a biopsy is taken, but the process can feel slow when you’re the one waiting. Asking your care team for a rough timeline at each step can help manage the uncertainty.
Screening for High-Risk Patients
For people with cirrhosis or chronic hepatitis B, liver cancer screening typically involves an ultrasound and AFP blood test every six months. The goal is to catch tumors when they’re small and most treatable. This is where the limitations of current tools become most relevant: small, well-differentiated tumors are the hardest to spot on imaging, and AFP misses about 15% of cancers entirely. Combining AFP with PIVKA-II or using MRI instead of ultrasound for screening in high-risk groups are approaches some centers have adopted to close these gaps.
Liquid biopsy, a blood test that detects fragments of tumor DNA or distinctive chemical patterns on circulating DNA, is an active area of development. These tests show promise for catching liver cancer earlier than current methods allow, but they haven’t yet replaced standard screening in routine clinical practice.